ENHABIT INC (EHAB) Stock Fundamental Analysis
USA - NYSE:EHAB - US29332G1022 - Common Stock
8.5 USD
+0.1 (+1.19%)
8.5 USD
0 (0%)
Taking everything into account, EHAB scores 3 out of 10 in our fundamental rating. EHAB was compared to 101 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of EHAB while its profitability can be described as average. EHAB has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
EHAB had positive earnings in the past year.
In the past year EHAB had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: EHAB reported negative net income in multiple years.
In the past 5 years EHAB always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of EHAB (-10.87%) is worse than 78.22% of its industry peers.
The Return On Equity of EHAB (-24.11%) is worse than 68.32% of its industry peers.
EHAB's Return On Invested Capital of 3.98% is in line compared to the rest of the industry. EHAB outperforms 48.51% of its industry peers.
The Average Return On Invested Capital over the past 3 years for EHAB is significantly below the industry average of 9.33%.
The 3 year average ROIC (3.74%) for EHAB is below the current ROIC(3.98%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.87% | ||
| ROE | -24.11% | ||
| ROIC | 3.98% |
ROA(3y)-7%
ROA(5y)-1.92%
ROE(3y)-15.77%
ROE(5y)-6.79%
ROIC(3y)3.74%
ROIC(5y)4.76%
1.3 Margins
EHAB has a Operating Margin of 5.31%. This is in the better half of the industry: EHAB outperforms 61.39% of its industry peers.
In the last couple of years the Operating Margin of EHAB has declined.
EHAB has a Gross Margin of 48.88%. This is in the better half of the industry: EHAB outperforms 75.25% of its industry peers.
EHAB's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.31% | ||
| PM (TTM) | N/A | ||
| GM | 48.88% |
OM growth 3Y-29.61%
OM growth 5Y-4.28%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.12%
GM growth 5Y-1.19%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), EHAB is destroying value.
Compared to 1 year ago, EHAB has more shares outstanding
Compared to 1 year ago, EHAB has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.59, we must say that EHAB is in the distress zone and has some risk of bankruptcy.
EHAB has a Altman-Z score of 1.59. This is in the lower half of the industry: EHAB underperforms 63.37% of its industry peers.
The Debt to FCF ratio of EHAB is 9.72, which is on the high side as it means it would take EHAB, 9.72 years of fcf income to pay off all of its debts.
EHAB's Debt to FCF ratio of 9.72 is in line compared to the rest of the industry. EHAB outperforms 49.51% of its industry peers.
EHAB has a Debt/Equity ratio of 0.83. This is a neutral value indicating EHAB is somewhat dependend on debt financing.
EHAB has a Debt to Equity ratio (0.83) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 9.72 | ||
| Altman-Z | 1.59 |
ROIC/WACC0.44
WACC9.06%
2.3 Liquidity
A Current Ratio of 1.57 indicates that EHAB should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.57, EHAB is in line with its industry, outperforming 53.47% of the companies in the same industry.
EHAB has a Quick Ratio of 1.57. This is a normal value and indicates that EHAB is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of EHAB (1.57) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.57 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 30.43% over the past year.
Looking at the last year, EHAB shows a decrease in Revenue. The Revenue has decreased by -0.39% in the last year.
EHAB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.07% yearly.
EPS 1Y (TTM)30.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.71%
Revenue 1Y (TTM)-0.39%
Revenue growth 3Y-2.21%
Revenue growth 5Y-1.07%
Sales Q2Q%2.11%
3.2 Future
The Earnings Per Share is expected to grow by 0.40% on average over the next years.
EHAB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.57% yearly.
EPS Next Y139.94%
EPS Next 2Y62.45%
EPS Next 3Y43.04%
EPS Next 5Y0.4%
Revenue Next Year2.84%
Revenue Next 2Y3.58%
Revenue Next 3Y3.8%
Revenue Next 5Y5.57%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 28.33, which means the current valuation is very expensive for EHAB.
Compared to the rest of the industry, the Price/Earnings ratio of EHAB indicates a somewhat cheap valuation: EHAB is cheaper than 60.40% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.77, EHAB is valued at the same level.
EHAB is valuated correctly with a Price/Forward Earnings ratio of 15.34.
Based on the Price/Forward Earnings ratio, EHAB is valued a bit cheaper than the industry average as 77.23% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of EHAB to the average of the S&P500 Index (23.23), we can say EHAB is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.33 | ||
| Fwd PE | 15.34 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, EHAB is valued a bit cheaper than the industry average as 69.31% of the companies are valued more expensively.
EHAB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EHAB is cheaper than 90.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.74 | ||
| EV/EBITDA | 10.43 |
4.3 Compensation for Growth
EHAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as EHAB's earnings are expected to grow with 43.04% in the coming years.
PEG (NY)0.2
PEG (5Y)N/A
EPS Next 2Y62.45%
EPS Next 3Y43.04%
5. Dividend
5.1 Amount
EHAB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
8.5
+0.1 (+1.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners103.04%
Inst Owner ChangeN/A
Ins Owners2.32%
Ins Owner Change14.61%
Market Cap430.87M
Analysts76.36
Price Target9.56 (12.47%)
Short Float %3.52%
Short Ratio3.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)38.27%
Min EPS beat(2)23.34%
Max EPS beat(2)53.19%
EPS beat(4)2
Avg EPS beat(4)6.47%
Min EPS beat(4)-28.32%
Max EPS beat(4)53.19%
EPS beat(8)5
Avg EPS beat(8)23.89%
EPS beat(12)6
Avg EPS beat(12)6.38%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.59%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)-0.95%
Revenue beat(4)0
Avg Revenue beat(4)-3.12%
Min Revenue beat(4)-4.98%
Max Revenue beat(4)-0.95%
Revenue beat(8)0
Avg Revenue beat(8)-3.4%
Revenue beat(12)0
Avg Revenue beat(12)-3.61%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.35%
EPS NY rev (1m)0%
EPS NY rev (3m)12.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.33 | ||
| Fwd PE | 15.34 | ||
| P/S | 0.42 | ||
| P/FCF | 8.74 | ||
| P/OCF | 8.16 | ||
| P/B | 0.78 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.43 |
EPS(TTM)0.3
EY3.53%
EPS(NY)0.55
Fwd EY6.52%
FCF(TTM)0.97
FCFY11.44%
OCF(TTM)1.04
OCFY12.25%
SpS20.47
BVpS10.9
TBVpS-7.83
PEG (NY)0.2
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.87% | ||
| ROE | -24.11% | ||
| ROCE | 5.03% | ||
| ROIC | 3.98% | ||
| ROICexc | 4.12% | ||
| ROICexgc | 40.3% | ||
| OM | 5.31% | ||
| PM (TTM) | N/A | ||
| GM | 48.88% | ||
| FCFM | 4.75% |
ROA(3y)-7%
ROA(5y)-1.92%
ROE(3y)-15.77%
ROE(5y)-6.79%
ROIC(3y)3.74%
ROIC(5y)4.76%
ROICexc(3y)3.81%
ROICexc(5y)4.84%
ROICexgc(3y)39.56%
ROICexgc(5y)58.49%
ROCE(3y)4.73%
ROCE(5y)6.02%
ROICexcg growth 3Y-27.94%
ROICexcg growth 5YN/A
ROICexc growth 3Y-21.68%
ROICexc growth 5YN/A
OM growth 3Y-29.61%
OM growth 5Y-4.28%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.12%
GM growth 5Y-1.19%
F-Score5
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 9.72 | ||
| Debt/EBITDA | 5.49 | ||
| Cap/Depr | 12.46% | ||
| Cap/Sales | 0.34% | ||
| Interest Coverage | 1.46 | ||
| Cash Conversion | 63.46% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.57 | ||
| Altman-Z | 1.59 |
F-Score5
WACC9.06%
ROIC/WACC0.44
Cap/Depr(3y)51.64%
Cap/Depr(5y)35.82%
Cap/Sales(3y)1.58%
Cap/Sales(5y)1.12%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.71%
EPS Next Y139.94%
EPS Next 2Y62.45%
EPS Next 3Y43.04%
EPS Next 5Y0.4%
Revenue 1Y (TTM)-0.39%
Revenue growth 3Y-2.21%
Revenue growth 5Y-1.07%
Sales Q2Q%2.11%
Revenue Next Year2.84%
Revenue Next 2Y3.58%
Revenue Next 3Y3.8%
Revenue Next 5Y5.57%
EBIT growth 1Y49.73%
EBIT growth 3Y-31.17%
EBIT growth 5Y-5.31%
EBIT Next Year78.49%
EBIT Next 3Y24.83%
EBIT Next 5YN/A
FCF growth 1Y1073.81%
FCF growth 3Y-26.15%
FCF growth 5Y0%
OCF growth 1Y19.19%
OCF growth 3Y-25.39%
OCF growth 5Y-2.96%